In this episode of Investor Connect, we hear a pitch from Aether on addressing the global opioid epidemic with ATX-1209, a neuromodulator designed to modulate the mu-opioid receptor by suppressing dependence signals while preserving analgesic benefit when used alongside opioids, with additional development plans for opioid use disorder and neonatal opioid withdrawal syndrome (NOWS).

The team cites completed human safety work, clean toxicology, and consistent animal data across species, along with validation from neuroscientist Dr. Phil Skolnick, and outlines a stage-gated, capital-efficient plan to run two clinical studies in Australia over roughly 2.5 years for about $10M to reach a key value inflection point.

Ethair is raising $10M on a convertible note at a $13.3M pre-money valuation (with a lead investor already in for $4.5M on a $9M note), targeting an early exit if Phase 2A data shows reduced dependence scores with no loss of analgesia, or alternatively pursuing a pediatric orphan NOWS registrational study tied to a potential PRV voucher.

________________________________________________________________________

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org

Check out our other podcasts here: https://investorconnect.org/
For Investors check out: https://tencapital.group/investor-landing/
For Startups check out: https://tencapital.group/company-landing/
For eGuides check out: https:/_/tencapital.group/education/
For upcoming Events, check out https://tencapital.group/events/

For Feedback please contact info@tencapital.group

Please follow, share, and leave a review.

Music courtesy of Bensound.